Role of ASA in the primary and secondary prevention of cardiovascular events

Cardiovascular disease, which includes coronary heart disease, cerebrovascular disease and peripheral artery disease, is the leading cause of death in developed countries. Evidence from basic research, clinical investigations, observational epidemiologic studies and randomized clinical trials has pr...

Full description

Saved in:
Bibliographic Details
Published in:Baillière's best practice & research. Clinical gastroenterology 2012-04, Vol.26 (2), p.113-123
Main Authors: Casado-Arroyo, Rubén, MD, Bayrak, Fatih, MD, Sarkozy, Andrea, MD, PhD, Chierchia, Gian-Battista, MD, Asmundis, Carlo de, MD, PhD, Brugada, Pedro, MD, PhD
Format: Article
Language:English
Subjects:
Aspirin
Aspirin - adverse effects
Aspirin - therapeutic use
Cardiovascular disease
Cardiovascular Diseases - prevention & control
Gastroenterology and Hepatology
Heart attacks
Humans
Mortality
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - therapeutic use
Primary Prevention
Secondary Prevention
Sex Factors
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease, which includes coronary heart disease, cerebrovascular disease and peripheral artery disease, is the leading cause of death in developed countries. Evidence from basic research, clinical investigations, observational epidemiologic studies and randomized clinical trials has provided strong support for the benefits of aspirin in decreasing the risk of cardiovascular events in a wide range of pathologies in secondary prevention. Data in primary prevention have far more uncertainties. An overview for the evidence supporting the efficacy of aspirin in primary and secondary prevention of cardiovascular disease is discussed, including the relative and absolute benefit and the risks of side effects. Finally, future developments in the field directed towards individualized treatment strategies and novel antiplatelet agents are examined.
ISSN:1521-6918
1532-1916
DOI:10.1016/j.bpg.2012.01.013